State Street Corp Exagen Inc. Transaction History

State Street Corp

$2.36 Trillion
Q1 2025

A detailed history of State Street Corp transactions in Exagen Inc. stock. As of the latest transaction made, State Street Corp holds 33,691 shares of XGN stock, worth $261,105. This represents 0.0% of its overall portfolio holdings.

Number of Shares

33,691

Previous 33,691 -0.0%

Holding current value

$261,105

Previous $138,000 13.04%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$2.43 - $6.0 $14,580 - $36,000	6,000 Added 21.67%	33,691 $138,000
Q1 2024 May 15, 2024	SELL	$1.42 - $2.3 $8,520 - $13,799	-6,000 Reduced 17.81%	27,691 $44,000
Q2 2022 Aug 15, 2022	SELL	$4.18 - $7.74 $411,027 - $761,089	-98,332 Reduced 74.48%	33,691 $193,000
Q1 2022 May 16, 2022	BUY	$7.12 - $11.06 $32,602 - $50,643	4,579 Added 3.59%	132,023 $1.06 Million
Q4 2021 Feb 14, 2022	SELL	$8.97 - $14.08 $609 - $957	-68 Reduced 0.05%	127,444 $1.48 Million
Q3 2021 Nov 15, 2021	BUY	$10.25 - $15.21 $353,102 - $523,969	34,449 Added 37.02%	127,512 $1.73 Million
Q2 2021 Aug 16, 2021	BUY	$12.4 - $17.92 $314,228 - $454,110	25,341 Added 37.42%	93,063 $1.4 Million
Q1 2021 May 17, 2021	BUY	$13.9 - $22.0 $86,305 - $136,598	6,209 Added 10.09%	67,722 $1.19 Million
Q4 2020 Feb 16, 2021	SELL	$11.19 - $16.05 $16,874 - $24,203	-1,508 Reduced 2.39%	61,513 $812,000
Q3 2020 Nov 10, 2020	BUY	$10.56 - $16.69 $83,265 - $131,600	7,885 Added 14.3%	63,021 $683,000
Q2 2020 Aug 14, 2020	BUY	$11.0 - $16.7 $40,337 - $61,238	3,667 Added 7.12%	55,136 $684,000
Q1 2020 May 11, 2020	BUY	$12.7 - $25.95 $653,656 - $1.34 Million	51,469 New	51,469 $820,000

Others Institutions Holding XGN

# of Institutions

Shares Held

6.19M

Call Options Held

3.4K

Put Options Held

18.4K

View Full List

About EXAGEN INC.

Ticker XGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 16,260,400
Market Cap $126M
Description
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...

More about XGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Exagen Inc. Transaction History